Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas
MTDs and safety profiles are reported for LMP776 and LMP744. Target engagement by an indenoisoquinoline was measured for the first time in human samples.
Authors
- Shivaani Kummar (ORCID: https://orcid.org/0000-0001-6906-1627)
- Katherine V. Ferry‐Galow
- Geraldine O’Sullivan Coyne (ORCID: https://orcid.org/0000-0002-2918-6326)
- Deborah Wilsker
- Jan H. Beumer (ORCID: https://orcid.org/0000-0002-8978-9401)
- Larry Rubinstein (ORCID: https://orcid.org/0000-0002-9720-9737)
- Barry C. Johnson (ORCID: https://orcid.org/0000-0001-9482-2248)
- Murielle Hogu
- Joseph M. Covey (ORCID: https://orcid.org/0000-0002-5696-8999)
- James H. Doroshow (ORCID: https://orcid.org/0000-0002-4463-1790)
- Yves Pommier (ORCID: https://orcid.org/0000-0002-3108-0758)
- Joshua J. Deppas (ORCID: https://orcid.org/0000-0002-9093-7459)
- Alice P. Chen (ORCID: https://orcid.org/0000-0002-1426-853X)
- Richard Piekarz (ORCID: https://orcid.org/0000-0002-3591-7893)
- Brian Ko
- S. Percy Ivy (ORCID: https://orcid.org/0000-0001-7747-072X)
- Melinda G. Hollingshead (ORCID: https://orcid.org/0000-0002-1207-1397)
- Liza Cosca Villaruz (ORCID: https://orcid.org/0000-0001-7456-523X)
- Julianne L. Holleran (ORCID: https://orcid.org/0000-0002-3738-8200)
- Nancy Young Moore
- Ralph E Parchhment
Institutions
- Leidos (United States) (US)
- National Institutes of Health (US)
- Oregon Health & Science University (US)
- University of Pittsburgh (US)
- Zimmer Biomet (United States) (US)
- UPMC Hillman Cancer Center (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- Science Applications International Corporation (United States) (US)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1007/s00280-025-04778-5
- Citations
- 1
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- National Cancer Institute